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Pure Red Blood Cell 
Aplasia and 
Isoniazid Use
To the Editor: Isoniazid is a fi rst-
line drug in the treatment of tuberculo-
sis; its uses include prevention as well 
as cure. Isoniazid is usually well toler-
ated, although its common side effects 
include gastrointestinal discomfort, 
rash, allergy, hepatitis, and peripheral 
neuropathy. Hematologic disorders 
such as eosinophilia, thrombocytope-
nia, and autoimmune hemolytic ane-
mia are rarely reported (1). Pure red 
cell aplasia (PRCA) is an uncommon 
disorder in adults. PRCA occurs sec-
ondary to drug exposure in 5% of pa-
tients; ≈30 drugs have been implicated 
(2), and few reports involving isonia-
zid have been published. We report a 
case of isoniazid-induced PRCA.
In 2006, a 79-year-old woman 
sought care at a public assistance 
hospital in Paris; she reported having 
had asthenia, breathlessness, and de-
creased appetite for 2 weeks. She had 
had node-negative, localized gastric 
adenocarcinoma 2 years earlier, which 
had been treated by partial gastrec-
tomy, and pulmonary tuberculosis in 
1948, which had been treated by par-
tial pneumonectomy. As a result of a 
pleuropulmonary tuberculosis relapse 
diagnosed 6 weeks earlier, she was re-
ceiving antituberculous treatment with 
rifampin (400 mg/day), isoniazid (150 
mg/day), ethambutol (800 mg/day), 
and pyrazinamide (1,000 mg/day). 
She received no other concomitant 
medications.
Her initial physical examination 
showed nothing abnormal. Laboratory 
analysis showed hemoglobin 6.3 g/
dL, leukocyte and thrombocyte counts 
within normal limits, 1% reticulocytes, 
and zero schizocytes. Other test results 
(liver and renal function, serum folate 
and vitamin B12 levels, lactic dehy-
drogenase levels, C-reactive protein, 
serum protein electrophoresis, direct 
and indirect Coombs tests, and antinu-
clear antibody tests) were within nor-
mal limits, as were viral serologic test 
results (HIV, hepatitis B virus, hepa-
titis C virus, parvovirus B19). Upper 
and lower digestive tract endoscopic 
examination and carcinoembryonic 
antigen showed no abnormalities, 
which lessened the likelihood of a tu-
mor relapse. Bone marrow aspiration 
from the sternum showed a hypocel-
lular marrow with complete absence 
of the erythroid series, a normal my-
eloid series, and megakaryocytes. The 
marrow fi ndings were consistent with 
PRCA.
In view of previous reports of 
isoniazid-induced PRCA (3–5), we 
suspected this drug to be responsible 
in this case. Isoniazid was withdrawn, 
and other antituberculous drugs were 
continued. The patient’s hemoglobin 
level rose to 10.6 g/dL and reticu-
locyte count to 3% over 10 days; no 
blood transfusion was required.
Drug-induced PRCA is a rare 
blood disorder in adults and has al-
ready been reported in isoniazid-treat-
ed patients (3–5). For this patient, other 
causes for anemia (e.g., drug-induced 
hemolytic anemia, digestive malignan-
cies, viral causes known to date, hema-
tologic malignancies, and autoimmune 
disorders) were excluded (2).
The favorable outcome after iso-
niazid withdrawal increased the like-
lihood that isoniazid was the cause. 
Although rechallenge with isoniazid 
could have confi rmed isoniazid as the 
cause, it is not an ethical option because 
of the hazardous adverse effects.
The exact mechanism for isonia-
zid-induced PRCA remains unclear, 
but the demonstration of antibodies 
reacting with nucleated red blood cells 
in ≈50% of cases suggests an induc-
tion of autoimmunity (4,5). This hy-
pothesis is supported by previously re-
ported cases in which PRCA relapses 
occurred when treatment with isonia-
zid was resumed (3,5). The intrinsic 
imputability of isoniazid also relies on 
the lack of a dose-effect relationship 
and the delay between the introduction 
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of isoniazid and the onset of PRCA, 
which can occur up to 6 months after 
start of treatment (3).
Clinicians treating patients with 
tuberculosis must be aware of this 
adverse reaction because failure to 
identify and discontinue isoniazid in 
patients with such a condition might 
lead to their illness and death. Given 
the ongoing worldwide HIV pandemic 
and the increase in tuberculosis it in-
duces, such adverse effects are more 
likely to be reported in the next few 
years.
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Failure of Isoniazid 
Chemoprophylaxis 
during Infl iximab 
Therapy
 To the Editor: A patient with an-
kylosing spondylitis was treated with 
infl iximab, a tumor necrosis factor 
(TNF) blocker that has been associated 
with reactivation of latent tuberculosis 
(TB). Because of reactivity in testing 
with purifi ed protein derivative, isoni-
azid chemoprophylaxis was started 2 
weeks before infl iximab therapy. Four 
months later, a cavitary lung infec-
tion developed in the patient, caused 
by isoniazid-resistant Mycobacterium 
kansasii.
To our knowledge, this is the fi rst 
documented case of failure of isonia-
zid prophylaxis due to the emergence 
of isoniazid-resistant mycobacteria in 
patients receiving infl iximab therapy. 
TNF blockers have contributed to the 
control of rheumatic diseases (1). Many 
of the damaging infl ammatory mecha-
nisms that they inhibit are important 
in maintaining TB in the latent phase. 
Consequently, drugs that target TNF 
functions have been associated with 
an increased risk of TB (2). For these 
reasons, prophylactic chemotherapy 
should be offered to patients with la-
tent TB (3). We show the failure of iso-
niazid chemoprophylaxis in a patient 
receiving infl iximab therapy in whom 
lung infection developed, caused by 
isoniazid-resistant M. kansasii.
A 39-year-old man with anky-
losing spondylitis was admitted to 
Jimenez Diaz Foundation hospital, 
Madrid, because of fever and lung in-
fi ltrates. He had been receiving anti-
infl ammatory drug therapy without 
amelioration of his symptoms. There-
fore, treatment with infl iximab was 
considered. Fifteen years before, the 
patient’s father had had pulmonary 
TB caused by M. tuberculosis that was 
susceptible to fi rst-line antitubercu-
lous drugs, and the patient was given 
chemoprophylaxis with isoniazid, 300 
mg/day, during a 9-month period. Be-
fore beginning infl iximab therapy, the 
patient was again given chemopro-
phylaxis with isoniazid, 300 mg/day, 
because a tuberculin test with 5 units 
of purifi ed protein derivative showed 
an induration of 18 mm at 72 hours. 
Results of chest radiographs were nor-
mal, and cultures for mycobacteria 
were negative. Results of HIV testing 
were also negative.
After 4 months of infl iximab 
therapy, fever, cough, and sputum pro-
duction developed. New radiographs 
showed bilateral upper lung fi eld in-
fi ltrates with cavitary lesions. Three 
acid-fast stains of sputum were posi-
tive, and treatment with rifampin, iso-
niazid, pyrazinamide, and ethambutol 
was started. 
A heavy growth of photochro-
mogenic mycobacteria was detected 
in 3 sputum cultures. The isolate was 
identifi ed as M. kansasii genotype 1 
by using common biochemical tests 
and PCR–restriction fragment length 
polymorphism analysis of the hsp65 
gene (4). Susceptibility tests showed 
resistance to isoniazid (>5 μg/mL), 
streptomycin, pyrazinamide, p-ami-
no-salicylic acid, and kanamycin but 
susceptibility to rifampin, ethambutol, 
and fl uoroquinolones. 
Treatment was continued with a 
combination of rifampin, levofl oxa-
cin, and ethambutol. Sputum cultures 
taken after 4, 6, and 9 months of an-
timicrobial drug therapy were nega-
tive. After 20 months of treatment, the 
patient was doing well with a partial 
resolution of lung infi ltrates, and new 
cultures were negative. 
Isoniazid chemoprophylaxis can 
effectively lessen the likelihood of ac-
tive TB in patients treated with TNF 
antagonists (5). However, at least 1 
failure of TB chemoprophylaxis in a 
severely immunocompromised patient 
treated with infl iximab and methotrex-
ate has been published (6). Our patient 
is unique because the mycobacterial 
lung infection seemed to emerge as 
a result of the lack of activity of iso-
The opinions expressed by authors contribut-
ing to this journal do not necessarily refl ect the 
opinions of the Centers for Disease Control and 
Prevention or the institutions with which the au-
thors are affi liated.
